News: Drug Discovery

Next Page »« Previous Page

Have You Checked Out Cancer Connect Yet?

Thursday, February 10th, 2011

Vanderbilt-Ingram Cancer Center has joined with the national CancerConnect.com initiative to launch a new online support community for people impacted by cancer, including patients, family members, friends and advocates. Participants don’t have to be a Vanderbilt-Ingram patient or family member to join the online community. There they can share stories, ask questions and learn from […]

New Website Showcases Discovery

Friday, February 4th, 2011

The latest news about discoveries by Vanderbilt University researchers is now available on a new online news channel, Research News @ Vanderbilt. “We have created this website to open the doors of our laboratories and lecture halls to a broad audience and share with them the excitement of discoveries being made every day at Vanderbilt,” […]

Grant Bolsters Pancreatic Cancer Research

Monday, January 31st, 2011

Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, has received a $2.5 million grant to fund research on drugs for the treatment of pancreatic cancer. The three-year award from the Lustgarten Foundation will support Fesik’s work on targeting K-Ras, a protein that is mutated in 90 percent of pancreatic cancer patients. Approximately 43,140 patients […]

Spicing Up Cancer Prevention

Tuesday, January 25th, 2011

Curcumin – the active ingredient that flavors curries and gives the Indian spice turmeric its yellow color – is being studied for its ability to prevent tumor development. Its efficacy, however, is limited by chemical and metabolic instability. Previous studies have focused on the non-enzymatic (not mediated by a protein) cleavage of curcumin into smaller […]

Seven VU Faculty Honored

Wednesday, January 12th, 2011

Nashville, Tenn. – Seven Vanderbilt University faculty members, including 6 who are members of the Vanderbilt-Ingram Cancer Center, have been elected Fellows of the American Association for the Advancement of Science (AAAS), an honor bestowed upon them by their AAAS peers. They are among 503 AAAS members from around the country who achieved this honor […]

Share Your Stories, Art

Wednesday, January 5th, 2011

Tabula Rasa, the School of Medicine’s journal of medical humanities, is now accepting submissions for its 2010-2011 issue. The theme of this year’s journal is “Transformation: How Illness and Healing Change Us.” All submissions that meet the criteria (see below) will be featured on the Tabula Rasa website, and many of the selected submissions will […]

Call Center Operations Restored

Tuesday, January 4th, 2011

Update as of Thursday, Jan. 6: Call Center staff have been relocated to temporary locations, with phones and computers, so our service has been restored. Thanks to everyone for their patience while we addressed this unexpected situation. Kudos to our team for their dedication to finding a way to get back on line for our […]

New Online Community for Survivors

Friday, December 31st, 2010

Editor’s note: Cynthia Floyd Manley, Vanderbilt-Ingram Cancer Center’s associate director for communications, will appear on Lifetime Television’s The Balancing Act on Monday, Jan. 3, to discuss social networking for cancer survivors and caregivers. Vanderbilt-Ingram Cancer Center has joined with the national CancerConnect.com initiative to launch a new online community for people impacted by cancer. As […]

Clinical Trials in Era of Targeted Therapies

Friday, December 17th, 2010

Cousins with melanoma caused by the same genetic mutation enroll in a randomized clinical trial of a promising experimental drug that targets the mutation. Randomly assigned to different groups, one young man gets the new drug, experiences dramatic shrinkage of his tumors and is alive nine months later, while his cousin receives current therapy — […]

Clue to Melanoma Drug Resistance

Friday, December 17th, 2010

Patients with metastatic melanoma being treated with the new investigational cancer drug PLX4032 are showing strong responses, with an 80 percent anti-tumor response rate among patients whose tumors are positive for the B-RAF (V600E) gene mutation. However, in all too many cases, patients are developing resistance to the drug and their cancer is beginning to […]